SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 589.60 |
| Enterprise Value ($M) | 396.37 |
| Book Value ($M) | 236.20 |
| Book Value / Share | 4.90 |
| Price / Book | 2.50 |
| NCAV ($M) | 227.04 |
| NCAV / Share | 4.71 |
| Price / NCAV | 2.60 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.28 |
| Return on Assets (ROA) | -0.65 |
| Return on Equity (ROE) | -0.74 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 15.29 |
| Current Ratio | 15.29 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 244.49 |
| Assets | 253.65 |
| Liabilities | 17.45 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -74.66 |
| Net Income | -67.67 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -53.55 |
| Cash from Investing | -22.45 |
| Cash from Financing | 187.63 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Cormorant Asset Management, LP | 0.00 | -100.00 | |
| 13G/A | Commodore Capital Lp | 4.40 | 30.28 | |
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 6.40 | 35.28 | |
| 13G/A | Lynx1 Capital Management LP | 4.99 | -24.29 | |
| 13G/A | Alger Associates Inc | 7.80 | -4.37 | |
| 13G/A | Baker Bros. Advisors Lp | 3.40 | 8.45 | |
| 13G/A | Bain Capital Life Sciences Opportunities III, LP | 4.70 | 0.00 | |
| 13G/A | Nichtberger Steven | 5.40 | 14.37 | |
| 13G/A | Flynn James E | 4.69 | -14.20 | |
| 13G/A | Adage Capital Partners Gp, L.l.c. | 9.47 | 50.99 | |
| 13G | State Street Corp | 6.05 | ||
| 13G | BlackRock Inc. | 10.30 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 207,907 | 352,057 | 59.05 | |
| 115,225 | 328,710 | 35.05 | |
| 113,780 | 493,093 | 23.07 | |
| 99,955 | 525,379 | 19.03 | |
| 152,449 | 370,969 | 41.09 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BMRN – BioMarin Pharmaceutical Inc. | BOLT – Bolt Biotherapeutics, Inc. |
| BPMC – Blueprint Medicines Corporation | CCCC – C4 Therapeutics, Inc. |
| CGC – Canopy Growth Corporation |
Financial data and stock pages provided by
Fintel.io